Conception of Circular Interfering RNA and production’s strategy
Guillaume Plane, CEO, MitoProd SA

Interfering RNAs represent a powerful tool for the Pharmaceutical Industry. Indeed, the stability, quality, in vivo efficiency and delivery of these molecules represent major challenges for their development. Basically, by circularizing the primary transcript and thus removing extremities, MitoProd brings an innovative solution to face most of these challenges. In association with MitoProd innovative technology for RNA manufacturing, based on the fermentation of Saccharomyces cerevisiae yeast, Circular Interfering RNAs (ciRNA®s) offer some major advantages for the development of siRNA-based drugs.